• Calliditas virtual R&D Day on
    January 20, 2021

  • Key Opinion Leader (KOL) Perspectives webinar

    March 10, 2021 at 10:00am Eastern Time.

  • Calliditas secures $75 million term loan facility


Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.


A potential treatment for patients with IgA nephropathy at risk of developing ESRD.

IgA Nephropathy HCP Site

Learn the hidden truth about IgA nephropathy, watch videos on the source of the disease, discover the role that the gut plays in IgAN, and more.

Share price Sweden

Share price US

Interim Report Q1 2021

On May 18, 2021, at 07:00 CEST, Calliditas Therapeutics published its interim report for the first quarter 2021. A conference call will be held to present and discuss the results, at 2.30 pm CEST.